Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States
Abstract
Background: Radical prostatectomy (RP) and radiotherapy (RT) are standard‐of‐care treatments for localized prostate cancer. The authors studied the utilization and total health care and patient‐incurred costs of RP and RT in the United States using the Merative MarketScan Medicare (Medicare Supplemental and Coordination of Benefits [MDCR]) and Commercial (Commercial Claims and Encounters [CCAE]) databases.Methods: Men were identified who had nonmetastatic prostate cancer treated with RP, external‐beam RT (EBRT), brachytherapy (BT), EBRT combined with BT (EBRT + BT), stereotactic body RT (SBRT), or proton‐beam therapy (PBT) between 2009 and 2022. Year‐to‐year treatment utilization was compared using the Kendall Tau‐b test. Mean total health care and patient out‐of‐pocket costs within 12 months of treatment were compared using the Kruskal–Wallis test.Results: In the MDCR database, 44,937 patients were identified who received treatment with RP (n = 12,879), EBRT (n = 26,193), BT (n = 926), EBRT + BT (n = 4706), PBT (n = 57), or SBRT (n = 176). Between 2009 and 2021, EBRT use increased from 52.5% to 62.2% (p for trend < .001), SBRT increased from 0.4% to 0.5% (p < .001), BT decreased from 3.1% to 1.0% (p < .001), and EBRT + BT decreased from 14.8% to 6.8% (p < 0.001); whereas use remained similar for RP (from 29.1% to 29.4%; p = .82) and PBT (from 0.1% to 0.1%; p = .93). In the CCAE database, 75,626 patients were identified who received treatment with RP (n = 50,278), EBRT (n = 16,985), BT (n = 1243), EBRT + BT (n = 6811), PBT (n = 92), or SBRT (n = 217). EBRT use increased from 20.0% to 24.9% (p < .001), SBRT increased from 0.1% to 0.8% (p < .001), BT decreased from 2.5% to 0.7% (p < .001), and EBRT + BT decreased from 10.6% to 7.4% (p < .001); whereas use remained similar for RP (from 66.8% to 66.1%; p for trend = .82), and PBT (from 0.1% to 0.1%; p for trend = .76). In the MDCR and CCAE databases, PBT had the highest total cost, whereas BT had the lowest.Conclusions: Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.Keywords
This publication has 19 references indexed in Scilit:
- Increasing Use of Shorter-Course Radiotherapy for Prostate CancerJAMA Oncology, 2023
- Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs CohortJAMA Network Open, 2021
- Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate‐specific antigen screening in 2012Cancer, 2019
- How might financial pressures have impacted brachytherapy? A proposed narrative to explain the declines in cervical and prostate brachytherapy utilizationBrachytherapy, 2019
- Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015JAMA, 2019
- Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancerBrachytherapy, 2018
- Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate CancerJAMA, 2018
- Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancerBrachytherapy, 2012
- Dose–Volume Comparison of Proton Therapy and Intensity-Modulated Radiotherapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008